THERMO FISHER SCIENTIFIC INC
For the period ended Dec 31, 2024. Filed Feb 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 20, 2025
TMO$718.20-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31,
| December 31, | December 31, | |
|---|---|---|
| (In millions except share and per share amounts) | 2024 | 2023 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $4,009 | $8,077 |
| Short-term investments | 1,561 | 3 |
| Accounts receivable, less allowances of $173 and $193 | 8,191 | 8,221 |
| Inventories | 4,978 | 5,088 |
| Contract assets, net | 1,435 | 1,443 |
| Other current assets | 1,964 | 1,757 |
| Total current assets | 22,137 | 24,589 |
| Property, plant and equipment, net | 9,306 | 9,448 |
| Acquisition-related intangible assets, net | 15,533 | 16,670 |
| Other assets | 4,492 | 3,999 |
| Goodwill | 45,853 | 44,020 |
| Total assets | $97,321 | $98,726 |
| Liabilities, redeemable noncontrolling interest and equity | ||
| Current liabilities: | ||
| Short-term obligations and current maturities of long-term obligations | $2,214 | $3,609 |
| Accounts payable | 3,079 | 2,872 |
| Accrued payroll and employee benefits | 1,988 | 1,596 |
| Contract liabilities | 2,852 | 2,689 |
| Other accrued expenses | 3,199 | 3,246 |
| Total current liabilities | 13,332 | 14,012 |
| Deferred income taxes | 1,268 | 1,922 |
| Other long-term liabilities | 3,989 | 4,642 |
| Long-term obligations | 29,061 | 31,308 |
| Commitments and contingencies (Note 5) | ||
| Redeemable noncontrolling interest | 120 | 118 |
| Equity: | ||
| Thermo Fisher Scientific Inc. shareholders’ equity: | ||
| Preferred stock, $100 par value, 50,000 shares authorized; none issued | ||
| Common stock, $1 par value, 1,200,000,000 shares authorized; 443,841,240 and 442,188,634 shares issued | 444 | 442 |
| Capital in excess of par value | 17,962 | 17,286 |
| Retained earnings | 53,102 | 47,364 |
| Treasury stock at cost, 63,066,906 and 55,541,290 shares | (19,226) | (15,133) |
| Accumulated other comprehensive income/(loss) | (2,697) | (3,224) |
| Total Thermo Fisher Scientific Inc. shareholders’ equity | 49,584 | 46,735 |
| Noncontrolling interests | (33) | (11) |
| Total equity | 49,551 | 46,724 |
| Total liabilities, redeemable noncontrolling interest and equity | $97,321 | $98,726 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.